Last $4.11 USD
Change Today -0.02 / -0.48%
Volume 1.2M
EXEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Open
$4.11
Previous Close
$4.13
Day High
$4.17
Day Low
$4.08
52 Week High
01/22/14 - $8.41
52 Week Low
04/15/14 - $3.02
Market Cap
801.9M
Average Volume 10 Days
2.0M
EPS TTM
$-1.27
Shares Outstanding
195.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

227 Employees
Last Reported Date: 02/20/14
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $681.7K
Executive Vice President of Exelixis
Total Annual Compensation: $617.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $577.3K
Consultant
Total Annual Compensation: $689.2K
Compensation as of Fiscal Year 2013.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Exelixis, Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total Revenue was $6,562,000 compared with $11,856,000 for the same period last year. Loss from operations was $61,688,000 compared with $51,295,000 for the same period last year. Net loss was $73,410,000 or $0.38 basic and diluted per share compared with $62,161,000 or $0.34 basic and diluted per share for the same period last year. For the six months, the company reported total Revenue was $11,467,000 compared with $21,525,000 for the same period last year. Loss from operations was $126,676,000 compared with $85,305,000 for the same period last year. Net loss was $148,029,000 or $0.77 basic and diluted per share compared with $106,890,000 or $0.58 basic and diluted per share for the same period last year. The increased net loss was primarily due to a decrease in license and contract revenues, which was partially offset by an increase in product revenues, and increases in research and development expenses and selling, general and administrative expenses.

Exelixis, Inc. to Report Q2, 2014 Results on Jul 31, 2014

Exelixis, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

Exelixis, Inc., Q2 2014 Earnings Call, Jul 31, 2014

Exelixis, Inc., Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $4.11 USD -0.02

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $6.06 USD +0.08
Array BioPharma Inc $3.83 USD -0.10
CrystalGenomics Inc 15,500 KRW -250.00
CTI BioPharma Corp $2.55 USD -0.01
Evotec AG €3.66 EUR -0.02
View Industry Companies
 

Industry Analysis

EXEL

Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.8x
Price/Book 248.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit www.exelixis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.